drugset
drugset / Trial / NCT06238336

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

NCT06238336 ↗

Phase 2/3 Unknown 30 enrolled Shanxi Bethune Hospital
NaSingle-groupOpen-labelTreatment

Summary

The trial is designed as an early exploratory single-centre, open, single-arm clinical trial. The trial is planned to evaluate the safety and efficacy of CAR-T for the treatment of relapsed refractory malignant haematological tumours. The trial is divided into five visit periods as follows: screening period, non-myeloablative pretreatment, short-term follow-up period, mid-term follow-up period and exit visit.

Timeline

Start
2020-06-15
Primary completion
2025-11-15
Completion
2025-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Axicabtagene Ciloleucel Cell therapy 1e+06 cells/kg —
Subject Axicabtagene Ciloleucel Cell therapy 2e+06 cells/kg —
Subject Axicabtagene Ciloleucel Cell therapy 4e+06 cells/kg —

Indications

hematopoietic and lymphoid cell neoplasm